Marker Proteins as a Guide in Clinical Management of Genitourinary Cancer

  • Paul H. Lange
Part of the Cancer Treatment and Research book series (CTAR, volume 6)

Abstract

Most of the noninvasive methods heretofore used to detect cancer entail identification of the images or anatomic effects of masses of tumor cells. Although this anatomical approach has been improved by such methods as computed tomography (CAT), it probably still is not able to detect masses of tumor cells smaller than 109 cells [1,2]. Thus, there is a pressing need for better methods of detecting cancer, not only for earlier diagnosis of tumors or recurrences but also for staging and judging the response to treatment. This necessarily has stimulated a search for molecular probes; that is, tumor markers.

Keywords

Prostaglandin Fibrinogen Oligosaccharide Neuroblastoma Plasminogen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hill BT: Cancer chemotherapy: the relevance of certain concepts of cell cycle kinetics. Biochim Biophys Acta 516: 389–417, 1978.PubMedGoogle Scholar
  2. 2.
    Husband J: Diagnostic techniques: their strengths and weaknesses. Br J Cancer 41 (Suppl 4): 21–9, 1980.Google Scholar
  3. 3.
    Yoshimoto Y, Wolfsen AR, Odell WD: Glycosylation, a variable in the production of hCG by cancers. Am J Med 67: 414–20, 1979.PubMedCrossRefGoogle Scholar
  4. 4.
    Lange PH: Immunologic testing of patients with genitourinary malignancies. Urol Clin North Am 6: 587–97, 1979.PubMedGoogle Scholar
  5. 5.
    Watson RA, Tang DB: The predictive value of prostatic acid phosphatase as a screening test for prostatic cancer. N Engl J Med 303: 497 - 9, 1980.PubMedCrossRefGoogle Scholar
  6. 6.
    Lange PH: Tumor immunology: a review of basic concepts with special reference to bladder cancer. American Urological Association Monogr 1: 119–32, 1982.Google Scholar
  7. 7.
    Benacerraf B, Unanue ER. Tumor immunology. In: Textbook of Immunology. ( Benacerraf B, ed.) Baltimore: Williams & Wilkins, 1979, pp. 196–213.Google Scholar
  8. 8.
    Old LJ: Cancer immunology: the search for specificity. Cancer Res 41: 361–75, 1981.PubMedGoogle Scholar
  9. 9.
    Gold P, Freedman SO: Specific carcinoembryonic antigens of the human digestive system. J Exp Med 122: 467–81, 1965.PubMedCrossRefGoogle Scholar
  10. 10.
    Fuks A, Shuster J, Gold P: Theoretical and practical consideration of the utility of the radioimmunoassay for carcinoembryonic antigen (CEA) in clinical medicine. In: Cancer Markers: Developmental and Diagnostic Significance. ( Sell S, ed) Clifton, NJ: Humana Press, 1980, pp. 315–27.Google Scholar
  11. 11.
    Shively JE, Todd CW. Carcinoembryonic antigen A: chemistry and biology. In: Cancer Markers: Developmental and Diagnostic Significance. ( Sell S, ed.) Clifton, NJ: Humana Press, 1980, pp. 295–314.Google Scholar
  12. 12.
    Chism SE: Oncofetal transplantation antigens. In: Cancer Markers: Developmental and Diagnostic Significance. ( Sell S, ed.) Clifton, NJ: Humana Press, pp. 115–32.Google Scholar
  13. 13.
    Benacerraf B, Unanue ER. Transplantation in Biology. In: Textbook of Immunology. ( Benacerraf B, ed.) Baltimore: Williams & Wilkins, 1979, pp. 125–54.Google Scholar
  14. 14.
    Forman J: Antigens and the major histocompatibility complex. In: Cancer Markers: Developmental and Diagnostic Significance ( Sell S, ed.) Clifton, NJ: Humana Press, 1980, pp. 133–68.Google Scholar
  15. 15.
    McDevitt HO: Regulation of the immune response by the major histocompatibility system. N Engl J Med 303: 1514–7, 1980.PubMedCrossRefGoogle Scholar
  16. 16.
    DeWolf WC, Lange PH, Einarson ME, Yunis EJ: HLA and testicular cancer. Nature 277: 216–7, 1979.PubMedCrossRefGoogle Scholar
  17. 17.
    DeWolf WC, Lange PH, Shepherd R, Martin-Alosco S, Yunis EJ: Association of HLA and renal cell carcinoma. Hum Immunol 2: 41–4, 1981.PubMedCrossRefGoogle Scholar
  18. 18.
    Neville AM, Cooper EH: Biochemical monitoring of cancer: a review. Ann Clin Biochem 13: 283–305, 1976.PubMedGoogle Scholar
  19. 19.
    Borek E: Transfer RNA and its by-products as tumor markers. In: Cancer Markers: Developmental and Diagnostic Significance ( Sell S, ed.) Clifton, NJ: Humana Press, 1980, pp. 445–62.Google Scholar
  20. 20.
    Irving CC: Biochemically detectable tumor markers in the urine of bladder cancer patients. Cancer Res 37: 2872–4, 1977.PubMedGoogle Scholar
  21. 21.
    Ruoslahti E, Hayman EG, Engvall E: Fibronectin. In: Cancer Markers: Developmental and Diagnostic Significance ( Sell S, ed.) Clifton, NJ: Humana Press, 1980, pp. 485–506.Google Scholar
  22. 22.
    Yogeeswaran G: Surface glycolipid and glycoprotein antigens. In: Cancer Markers: Developmental and Diagnostic Significance ( Sell S, ed.) Clifton, NJ: Humana Press, 1980, pp. 371–402.Google Scholar
  23. 23.
    Baldwin EW, Robins RA: Circulating immune complexes in cancer. In: Cancer Markers: Developmental and Diagnostic Significance ( Sell S, ed.) Clifton, NJ: Humana Press, 1980, pp. 507–31.Google Scholar
  24. 24.
    Sufrin G, Mirand EA, Moore RH, Chu TM, Murphy GP: Hormones in renal cancer. J Urol 117: 433–8, 1977.PubMedGoogle Scholar
  25. 25.
    Marshall FF, Walsh PC: Extrarenal manifestations of renal cell carcinoma. J Urol 117: 439–40, 1977.PubMedGoogle Scholar
  26. 26.
    Lubensky JD, Gangai MP: The hypercalcemia of genitourinary malignancy. J Urol 121: 259–61, 1979.PubMedGoogle Scholar
  27. 27.
    Cummings KB, Robertson RP: Prostaglandin: increased production by renal cell carcinoma. J Urol 118: 720–3, 1977.PubMedGoogle Scholar
  28. 28.
    Chu TM, Skulka SK, Mittleman AO, Murphy GP: Plasma carcinoembryonic antigen in renal cell carcinoma patients. J Urol 111: 742–4, 1974.PubMedGoogle Scholar
  29. 29.
    Guinan PD, Ablin RJ, Dubin A, Nourkayham S, Bush IM: Carcinoembryonic antigen test in renal cell carcinoma. Urology 5: 185–7, 1975.PubMedCrossRefGoogle Scholar
  30. 30.
    Hautmann R, Kisters R, Lutzeyer W: Diagnosis of renal tumor by gamma-glutamyltrans- peptidase (EC 2.3.2.2). Urology 7: 12–6, 1976.PubMedCrossRefGoogle Scholar
  31. 31.
    Hada T, Hagashino K, Yamamoto H et al: The presence of novel gamma-glutamyltrans- peptidase in newly established cell line from human renal cell carcinoma OUR-10. Surrey, UK: Int Soc Oncodev Biol Med, 7th Annual Meeting, 1979.Google Scholar
  32. 32.
    Veith F, Page M, Marceau N: Gamma-glutamyltranspeptidase isoenzyme in human hypernephromas. Surrey, UK: Int Soc Oncodev Biol Med, 7th Annual Meeting, 1979.Google Scholar
  33. 33.
    Clayman RV, Gonzalez R, Elliott AY, Dempsey ME: Differences in cholesterol transport by normal and malignant human kidney cells. Biochem Biophys Res Comm 92: 1355–61, 1980.PubMedCrossRefGoogle Scholar
  34. 34.
    Gonzalez R, Goldberg ME: Origins of intracellular cholesterol in renal-cell carcinoma. Lancet 1: 912, 1977.PubMedCrossRefGoogle Scholar
  35. 35.
    Clayman RV, Gonzalez R, Elliott AY, Gleason DE, Dempsey ME: Cholesterol uptake in heterotransplanted human renal cell cancer, (submitted).Google Scholar
  36. 36.
    Sanford EJ, Drago JR, Rohner TJ, Kessler GF, Sheehan L, Lipton A: Preliminary evaluation of urinary polyamines in the diagnosis of genitourinary tract malignancy. J Urol 113: 218–21, 1975.PubMedGoogle Scholar
  37. 37.
    Milano G, Schneider M, Cassuto J-P et al: Polyamines: comments on clinical utility in cancer: a review. Tumordiagnostik 3: 121–5, 1980.Google Scholar
  38. 38.
    de Iriarte EG, Lopez Garcia JA, Hidalgo L, Mendoza M, Martinez-Pineiro JA: L’alpha-2 globuline: un marqueur biologique potentiel dans le cancer du rein? Ann Urol (Paris) 13: 102–5, 1979.Google Scholar
  39. 39.
    Grubb W, Drylie DM, Cade R, Fuller TJ: Reversible systemic abnormalities associated with renal cell carcinoma. Urology 9: 269–72, 1977.PubMedCrossRefGoogle Scholar
  40. 40.
    Wahren B: Tumour markers in urology: aids in cancer diagnosis and management. Urol Res 7: 57–67, 1979.PubMedCrossRefGoogle Scholar
  41. 41.
    Kovarik S, Davidsohn I, Strjskal R: ABO antigens in cancer: detection with the mixed cell agglutination reaction. Arch Pathol 86: 12–21, 1968PubMedGoogle Scholar
  42. 42.
    DeCenzo JM, Howard P, Irish CE: Antigenic deletion and prognosis of patients with stage A transitional cell bladder carcinoma. J Urol 114: 874–8, 1975.PubMedGoogle Scholar
  43. 43.
    Lange PH, Limas C, Fraley EE: Tissue blood-group antigens and prognosis in low stage transitional cell carcinoma of the bladder. J Urol 119: 52–5, 1978.PubMedGoogle Scholar
  44. 44.
    Emmott RC, Javadpour N, Bergman SM, Soares T: Correlation of the cell surface antigens with stage and grade in cancer of the bladder. J Urol 121: 37–9, 1979.PubMedGoogle Scholar
  45. 45.
    Richie JP, Blute RD Jr, Waisman J: Immunologic indicators of prognosis in bladder cancer: the importance of cell surface antigens. J Urol 123: 22–4, 1980.PubMedGoogle Scholar
  46. 46.
    Johnson JD, Lamm DL: Prediction of bladder tumor invasion with the mixed cell agglutination test. J Urol 123: 25–8, 1980.PubMedGoogle Scholar
  47. 47.
    Newman AJ Jr, Carlton CE Jr, Johnson S: Cell surface A, B or (O)H blood group antigens as an indicator of malignant potential in stage A bladder carcinoma. J Urol 124: 27–9, 1980.PubMedGoogle Scholar
  48. 48.
    Limas C, Lange PH: Reactivity of transitional cell carcinoma of the urinary bladder for A, B, H isoantigens: its prognostic significance. In: Tumor Progression, ( Crispen RG, ed.) Amsterdam: Elsevier/North-Holland Biomedical Press, 1980, pp. 101–23.Google Scholar
  49. 49.
    Lange PH, Limas C: Tissue blood-group antigen testing in transitional cell carcinoma of the bladder. J Urol 124: 304, 1980.PubMedGoogle Scholar
  50. 50.
    Limas C, Lange PH: Altered reactivity for A, B, H antigens in transitional cell carcinomas of the urinary bladder: a study of the mechanisms involved. Cancer 46: 1366–73, 1980.PubMedCrossRefGoogle Scholar
  51. 51.
    Limas C, Lange PH: A, B, H antigen detectability in normal and neoplastic urothelium: influence of methodological factors. Cancer (in press).Google Scholar
  52. 52.
    Weinstein RS, Coon J, Alroy J, Davidsohn I: Detection and significance of tissue-associated blood group antigens (ABH(O)) in human carcinomas. In: Diagnostic Immunology. (DeLellis RA, Stenberg SS, eds). New York: Masson Publishing (in press).Google Scholar
  53. 53.
    Zimmerman R, Wahren B, Edsmyr F: Assessment of serial CEA determinations in urine of patients with bladder carcinoma. Cancer 46: 1802–9, 1980.PubMedCrossRefGoogle Scholar
  54. 54.
    Turner AG, Carter S, Higgins E, Glashan RW, Neville AM: The clinical diagnostic value of carcinoembryonic antigen (CEA) in haematuria. Br J Urol 49: 61–6, 1977.PubMedCrossRefGoogle Scholar
  55. 55.
    Murphy WM, Vandevoorde JP, Rao MK, Soloway MS: The clinical value of urinary carcinoembryonic antigen-like substances in urothelial cancer. J Urol 118: 806–8, 1977.PubMedGoogle Scholar
  56. 56.
    0rjasaeter H, Fossa SD, Schjolseth SA, Fjaestad K. Carcinoembryonic antigen (CEA) in plasma of patients with carcinoma of the bladder/urethra. Cancer 42: 287–95, 1978.PubMedCrossRefGoogle Scholar
  57. 57.
    Wajsman Z, Merrin CE, Chu TM, Moore RH, Murphy GP. Evaluation of biological markers in bladder cancer. J Urol 114: 879–83, 1975.PubMedGoogle Scholar
  58. 58.
    Javadpour N: Tumor markers in urologic cancer. Urology 16: 127–36, 1980.PubMedCrossRefGoogle Scholar
  59. 59.
    Pyrhonen S, Timonen T, Heikkinen A, Penttinen K, Alftan O, Saksela E, Wager O: Rheumatoid factor as an indicator of serum blocking activity and tumour recurrences in bladder tumours. Eur J Cancer 12: 87–94, 1976.PubMedCrossRefGoogle Scholar
  60. 60.
    Gupta N, Malavija N, Singh SM: Rheumatoid factor in bladder tumors. J Urol 120: 296–7, 1978.PubMedGoogle Scholar
  61. 61.
    Gozzo JJ, Gottschalk R, O’Brien P, Cronin W, Monaco AP: Use of heterogenous and monospecific antisera for the diagnosis of bladder cancer. J Urol 118: 748–51, 1977.PubMedGoogle Scholar
  62. 62.
    Gozzo JJ, Cronin WJ, O’Brien P, Monaco AP: Detection of tumor-associated antigens in urine from patients with bladder cancer. J Urol 124: 804–7, 1980.PubMedGoogle Scholar
  63. 63.
    O’Brien P, Gozzo JJ, Monaco AP: Urinary proteins as biological markers: bladder cancer diagnosis versus urinary tract infection. J Urol 124: 802–3, 1980.PubMedGoogle Scholar
  64. 64.
    Civantos F, Rywlin AM: Carcinomas with trophoblastic differentiation and secretion of chorionic gonadotrophins. Cancer 29: 789–98, 1972.PubMedCrossRefGoogle Scholar
  65. 65.
    Bruce AW, Mahan DE, Belville WD. The role of radioimmunoassay for prostatic acid phosphatase in prostatic carcinoma. Urol Clin North Am 7: 645–52, 1980.PubMedGoogle Scholar
  66. 66.
    Belville WD, Sepulveda RA, Bruce AW et al.: Bone marrow acid phosphatase by radioimmunoassay — three years’ experience. San Francisco: American Urological Association Annual Meeting, 1980.Google Scholar
  67. 67.
    Cooper JF: The radioimmunochemical measurement of prostatic acid phosphatase: current state of the art. Urol Clin North Am 7: 653–5, 1980.PubMedGoogle Scholar
  68. 68.
    Pontes JE: State of the art in immune diagnosis of early adenocarcinoma of the prostate. Urol Clin North Am 7: 667–73, 1980.PubMedGoogle Scholar
  69. 69.
    Vihko P, Lukkarinen O, Kontturi M, Vihko R: Effectiveness of radioimmunoassay of human prostate-specific acid phosphatase in the diagnosis and follow-up of therapy in prostatic carcinoma. Cancer Res 41: 1180–3, 1981.PubMedGoogle Scholar
  70. 70.
    Kuriyama M, Wang MC, Papsidero LD et al.: Immunologic detection of a prostate specific antigen in human prostate cancer (abstract 826). Proc Amer Soc Clin Oncol 1980.Google Scholar
  71. 71.
    Fair WR, Catalona WC, Ratliff TR, Heston WDW: Tumor markers for prostatic carcinoma: prostatic acid phosphatase (PAP) and creatine kinase (CK-BB). San Francisco: American Urological Association Annual Meeting, 1980.Google Scholar
  72. 72.
    Narayana AS, Feld R, Loening SA, Culp DA: A new serum marker for carcinoma of the prostate. San Francisco: American Urological Association Annual Meeting, 1980.Google Scholar
  73. 73.
    Hindsley JP Jr., Fried FA, Zweig MH et al.: Creatine kinase BB in prostatic carcinoma. San Francisco: American Urological Association Annual Meeting, 1980.Google Scholar
  74. 74.
    Bishop MC, Fellows GJ: Urine hydroxyproline excretion — a marker of bone metastases in prostatic carcinoma. Br J Urol 49: 711–6, 1977.PubMedCrossRefGoogle Scholar
  75. 75.
    Mooppan MMU, Wax SH, Kim H, Wang JC, Tobin MS: Urinary hydroxyproline excretion as a marker of osseous metastasis in carcinoma of the prostate. J Urol 123: 694–6, 1980.PubMedGoogle Scholar
  76. 76.
    Juengst D, Pickel A, Elsaesser E, Marx FJ, Karl HJ: Urinary cholesterol excretion in men with benign prostatic hyperplasia and carcinoma of the prostate. Cancer 43: 353–9, 1979.PubMedCrossRefGoogle Scholar
  77. 77.
    Belis JA, Cenedella J: Urinary nonesterified cholesterol excretion in adenocarcinoma of the prostate. Cancer 43: 1840–6, 1979.PubMedCrossRefGoogle Scholar
  78. 78.
    Grayhack JT, Wendel EF, Oliver L, Lee C: Analysis of specific proteins in prostatic fluid for detecting prostatic malignancy. J Urol 121: 295–9, 1979.PubMedGoogle Scholar
  79. 79.
    Kane RD, Mickey DD, Paulson DF: Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy. Urology 8: 559–62, 1976.PubMedCrossRefGoogle Scholar
  80. 80.
    Williams RD, Bronson DL, Elliott AY, Fraley EE: Production of carcinoembryonic antigen by human prostate epithelial cells in vitro. J Natl Cancer Inst 58: 1 1 15–6, 1977.Google Scholar
  81. 81.
    Williams RD, Bronson DL, Myl AD, Vandevoorde JP, Elliott AY: Carcinoembryonic antigen-like substance derived from human prostate. Cancer Res 39: 2447–50, 1979.PubMedGoogle Scholar
  82. 82.
    Broder LE, Weintraub BD, Rosen SW, Cohen MH, Tejada F: Placental proteins and their subunits as tumor markers in prostatic carcinoma. Cancer 40: 211–6, 1977.PubMedCrossRefGoogle Scholar
  83. 83.
    Webb K, Lin GH: Urinary fibronectin: potential as a biomarker in prostatic cancer. Invest Urol 17: 401–4, 1980.PubMedGoogle Scholar
  84. 84.
    Ablin RJ, Gonder MH, Soanes WA: Levels of immunoglobulins in the serum of patients with carcinoma of the prostate. Neoplasma 19: 61–5, 1972.PubMedGoogle Scholar
  85. 85.
    Lange PH: Cancer markers in germ-cell testicular tumors. In: Cancer Markers: Developmental and Diagnostic Significance. (Sell S, Wahren B, eds.) vol 2. Clifton, NJ: Humana Press (in press).Google Scholar
  86. 86.
    Lange PH, Mclntire KR, Waldmann TA: Tumor markers in testicular tumor: current status and future prospects. In: Testicular Tumors: Management and Treatment ( Einhorn LE, ed.) New York: Masson, 1980, pp. 69–81.Google Scholar
  87. 87.
    Norgaard-Pedersen B, Raghavan D: Germ-cell tumours: collaborative review. Oncodev Biol Med 1: 327–58, 1980.Google Scholar
  88. 88.
    Javadpour N: Applications of biological markers in testicular cancer. Cancer Treat Rep 63: 1643–7, 1979.PubMedGoogle Scholar
  89. 89.
    Lange PH, Vogelzang NJ, Goldman A, Kennedy BJ, Fraley EE: Marker half-life analysis in testicular tumor: a prognostic tumor. J Urol (in press).Google Scholar
  90. 90.
    Kohn J: The value of apparent half-life assay of alpha-1 fetoprotein in the management of testicular teratoma. In: Carcino-Embryonic Proteins. (Lehmann FG, ed.) vol 2. Amsterdam: Elsevier/North-Holland Biomedical Press, 1979, pp. 383–6.Google Scholar
  91. 91.
    Javadpour N, Chen HC: Radioimmunoassay of urinary chorionic gonadotropin: a sensitive marker in testicular cancer. J Urol 126: 176–81, 1981.PubMedGoogle Scholar
  92. 92.
    Goldenberg DM, Kim EE, Deland FH, van Nagell JR Jr., Javadpour N: Radioimmuno- detection of cancer with radioactive antibodies to human chorionic gonadotropin. Science 207: 1284–6, 1980.CrossRefGoogle Scholar
  93. 93.
    Goldenberg DM, Kim EE, Deland F et al.: Clinical studies on the radioimmunodetection of tumors containing alpha-fetoprotein. Cancer 45: 2500–5, 1980.PubMedCrossRefGoogle Scholar
  94. 94.
    Goldenberg DM, Deland FH, Kim EE, Primus FJ: Xenogeneic antitumor antibodies in cancer radioimmunodetection. Transplant Proc 12: 188–91, 1980.PubMedGoogle Scholar
  95. 95.
    Kurman RJ, Scardino PT, Mclntire KR, Waldmann TA, Javadpour N: Cellular localization of alpha-fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using an indirect immunoperoxidase technique: a new approach to classification utilizing tumor markers. Cancer 40: 2136–51, 1977.PubMedCrossRefGoogle Scholar
  96. 96.
    Lange PH, Nochomovitz LE, Rosai J et al.: Serum alpha-fetoprotein and human chorionic gonadotropin in patients with seminoma. J Urol 124: 472–8, 1980.PubMedGoogle Scholar
  97. 97.
    Johnson SAN, Grudzinskas JG, Gordon YB et al.: Pregnancy-specific betax-glycoprotein in plasma and tissue extract in malignant teratoma of the testis. Br Med J 1: 951–2, 1977.PubMedCrossRefGoogle Scholar
  98. 98.
    Rosen SW, Javadpour N, Calvert I, Kaminska J: Increased ‘pregnancy-specific’ betar glycoprotein in certain nonseminomatous germ cell tumors. JNCI (J Natl Cancer Inst) 62: 1439–41, 1979.Google Scholar
  99. 99.
    Javadpour N, Utz M, Soares T: Immunocytochemical discordance in localization of pregnancy specific beta-1 glycoprotein, alpha-fetoprotein and human chorionic gonadotropin in testicular cancers. J Urol 124: 615–6, 1980.PubMedGoogle Scholar
  100. 100.
    Lange PH, Bremner RD, Home CHW, Vessella RL, Fraley EE: Is SP-1 a marker for testicular cancer? Urology 15: 251–5, 1980.PubMedCrossRefGoogle Scholar
  101. 101.
    Wahren B, Holmgren PA, Stigbrand T: Placental alkaline phosphatase, alphafetoprotein and carcinoembryonic antigen in testicular tumors: tissue typing by means of cytologic smears. Int J Cancer 24: 749–53, 1979.PubMedCrossRefGoogle Scholar
  102. 102.
    Millan JL, Stigbrand T: ‘Sandwich’ enzyme immunoassay for placental alkaline phosphatase. Clin Chem 27: 2014–8, 1981.Google Scholar
  103. 103.
    Lange PH, Millan JL, Stigbrand T, Vessella RL, Ruoslahti E, Fishman WH: Placental alkaline phosphatase as a tumor marker for seminoma. Cancer Res (in press).Google Scholar
  104. 104.
    Bosl, GJ, Lange PH, Nochomovitz LE et al.: Tumor markers in advanced nonseminomatous testicular cancer. Cancer 47: 572–6, 1981.PubMedCrossRefGoogle Scholar
  105. 105.
    Milstein C: Monoclonal antibodies. Sci Am 243 (4): 66–74, 1980.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, The Hague / Boston / London 1982

Authors and Affiliations

  • Paul H. Lange

There are no affiliations available

Personalised recommendations